KR102001069B1 - A composition for improving inflammatory skin disease containing evergreen woody species - Google Patents
A composition for improving inflammatory skin disease containing evergreen woody species Download PDFInfo
- Publication number
- KR102001069B1 KR102001069B1 KR1020170125363A KR20170125363A KR102001069B1 KR 102001069 B1 KR102001069 B1 KR 102001069B1 KR 1020170125363 A KR1020170125363 A KR 1020170125363A KR 20170125363 A KR20170125363 A KR 20170125363A KR 102001069 B1 KR102001069 B1 KR 102001069B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- inflammatory skin
- present
- thunb
- cream
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 27
- 239000000284 extract Substances 0.000 claims abstract description 91
- 241000196324 Embryophyta Species 0.000 claims abstract description 34
- 239000002537 cosmetic Substances 0.000 claims abstract description 26
- 230000036541 health Effects 0.000 claims abstract description 15
- 235000013376 functional food Nutrition 0.000 claims abstract description 14
- 241001062872 Cleyera japonica Species 0.000 claims abstract description 11
- 241000615471 Elaeocarpus sylvestris Species 0.000 claims abstract description 11
- 235000015876 Elaeocarpus sylvestris Nutrition 0.000 claims abstract description 7
- 241001022534 Ellipticus Species 0.000 claims abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 239000000419 plant extract Substances 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 230000002363 herbicidal effect Effects 0.000 claims description 14
- 241000186427 Cutibacterium acnes Species 0.000 claims description 13
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 229940055019 propionibacterium acne Drugs 0.000 claims description 11
- 239000006210 lotion Substances 0.000 claims description 10
- 241000191967 Staphylococcus aureus Species 0.000 claims description 9
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 7
- 206010000496 acne Diseases 0.000 claims description 7
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 7
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 206010012442 Dermatitis contact Diseases 0.000 claims description 6
- 206010039792 Seborrhoea Diseases 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 208000010247 contact dermatitis Diseases 0.000 claims description 6
- -1 pack Substances 0.000 claims description 6
- 239000012675 alcoholic extract Substances 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 235000016709 nutrition Nutrition 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 3
- 235000019219 chocolate Nutrition 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000002453 shampoo Substances 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 235000008429 bread Nutrition 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000000118 hair dye Substances 0.000 claims description 2
- 235000015243 ice cream Nutrition 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 235000013372 meat Nutrition 0.000 claims description 2
- 235000013550 pizza Nutrition 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 235000013580 sausages Nutrition 0.000 claims description 2
- 235000011888 snacks Nutrition 0.000 claims description 2
- 235000014347 soups Nutrition 0.000 claims description 2
- 235000013616 tea Nutrition 0.000 claims description 2
- 235000013334 alcoholic beverage Nutrition 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 45
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 28
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 24
- 229920001817 Agar Polymers 0.000 description 14
- 239000008272 agar Substances 0.000 description 14
- 238000000605 extraction Methods 0.000 description 14
- 230000000845 anti-microbial effect Effects 0.000 description 13
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 13
- 239000000401 methanolic extract Substances 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 7
- 229960005323 phenoxyethanol Drugs 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 241000191940 Staphylococcus Species 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 6
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 6
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 6
- 229960002216 methylparaben Drugs 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000003780 hair follicle Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000002034 butanolic fraction Substances 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 239000004009 herbicide Substances 0.000 description 4
- 238000009629 microbiological culture Methods 0.000 description 4
- 210000002374 sebum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229940111793 eggplant extract Drugs 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 229960004592 isopropanol Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000010802 sludge Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 208000020154 Acnes Diseases 0.000 description 2
- 241001112695 Clostridiales Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000186429 Propionibacterium Species 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000036074 healthy skin Effects 0.000 description 2
- 239000002044 hexane fraction Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000282979 Alces alces Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 241000555676 Malassezia Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002036 chloroform fraction Substances 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000012437 perfumed product Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000015541 sensory perception of touch Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 상록성 목본식물 추출물을 포함하는 염증성 피부질환 개선용 조성물에 관한 것으로, 보다 구체적으로 상록성 목본식물 추출물 중에서 담팔수[Elaeocarpus sylvestris var. ellipticus (Thunb.) H. Hara] 추출물, 비쭈기나무(Cleyera japonica Thunb.) 추출물, 또는 이들의 조합을 유효성분으로 포함하는 염증성 피부질환 개선용 약제학적 조성물, 화장료 조성물 및 건강기능식품에 관한 것이다. The present invention relates to a composition for improving inflammatory skin diseases, which comprises an extract of an herbaceous woody plant. More specifically, the present invention relates to a composition for improving inflammatory skin diseases, which comprises Elaeocarpus sylvestris var. a cosmetic composition, and a health functional food, which comprises an ellipticus (Thunb.) H. Hara extract, a Cleyera japonica Thunb. extract, or a combination thereof as an active ingredient.
Description
본 발명은 상록성 목본식물 추출물을 포함하는 염증성 피부질환 개선용 조성물에 관한 것으로, 보다 구체적으로 상록성 목본식물 추출물 중에서 담팔수[Elaeocarpus sylvestris var. ellipticus (Thunb.) H. Hara] 추출물, 비쭈기나무(Cleyera japonica Thunb.) 추출물, 또는 이들의 조합을 유효성분으로 포함하는 염증성 피부질환 개선용 약제학적 조성물, 화장료 조성물 및 건강기능식품에 관한 것이다. The present invention relates to a composition for improving inflammatory skin diseases, which comprises an extract of an herbaceous woody plant. More specifically, the present invention relates to a composition for improving inflammatory skin diseases, which comprises Elaeocarpus sylvestris var. a cosmetic composition, and a health functional food, which comprises an ellipticus (Thunb.) H. Hara extract, a Cleyera japonica Thunb. extract, or a combination thereof as an active ingredient.
피부는 외부자극과 환경의 변화로부터 신체를 보호하고 촉각을 전달하는 인체 기관으로서, 젊음, 건강, 성적 능력의 상징적인 역할을 담당하고 있다. 현대사회에서의 피부는 외모적인 아름다움뿐만 아니라 자신의 표출하며 의상 및 메이크업과 함께 패션경향을 결정짓는 중요한 요소이다. 피부에서 발생하는 이상 현상의 원인으로는 유전적인 요인, 스트레스, 호르몬의 이상, 피부에 기생하는 모낭충 및 유해한 피부상재균 등에 있다. 건강한 피부에서는 유익균이 80%, 유해균이 20%의 비율로 존재하며, 피부는 약산성(pH 5.5)으로 유지된다. 이때 유익균은 땀에서 분비되는 면역항체와 결합하여 피부면역력을 높여준다. 또한 약산성일 때 건강한 피부막은 피부를 촉촉하게 유지하고 몸의 장벽(barrier)으로서 피부의 수분누출을 막으며, 비타민의 생합성을 돕는다. 잘못된 세정습관, 화학성분 또는 오일제품의 장기간 사용 및 신체 리듬(biorhythm)과 생리적인 변화에 따른 testosterone의 불균형 등은 피지선을 비대 시키고 피지의 분비를 왕성하게 한다. 과다 분비된 피지에 의해 모낭벽 세포에 이상각화가 일어나 모낭구가 막히면 피지가 배출되지 못하고 정체된다. 이에 피부는 항상성이 깨지고, 모공내의 미생물들이 성장하기 좋은 조건을 조성함으로서 혐기성균, 호기성 구균, 진균 등이 번식하게 된다. 이때 번식된 Propionibacterium acnes가 lipase를 분비함으로써 피지성분의 중성지방이 유리지방산으로 변화된다. 이후 모낭 주위에 백혈구가 밀집하여 모낭벽을 파괴한 뒤 모낭 내용물이 진피 내로 유입되어 염증이 발생한다.Skin is a human body that protects the body from external stimuli and environmental changes and transmits tactile senses, and plays a symbolic role of youth, health, and sexual ability. In modern society, skin is not only cosmetic beauty but also its own expression, and it is an important factor that determines fashion trend with costume and makeup. The causes of skin abnormalities include genetic factors, stress, hormonal abnormalities, parasitic parasites on the skin, and harmful skin infections. In healthy skin, beneficial bacteria are present at a ratio of 80% and harmful bacteria are present at a ratio of 20%, and the skin is maintained to be slightly acidic (pH 5.5). In this case, the beneficial gynecological secretion from the sweat secreted by the immune system is combined with immunity. In addition, when the acid is weak, the healthy skin keeps the skin moist, prevents water leaks from the skin as a barrier to the body, and helps the vitamins biosynthesis. Incorrect cleaning habits, long-term use of chemical or oil products, and imbalance of testosterone due to biorhythm and physiological changes may aggravate sebaceous glands and exacerbate sebum secretion. If the hair follicle is clogged with an abnormal angle to the hair cell wall cells by the excessive secreted sebum, sebum will not be discharged and it will stagnate. Thus, the skin becomes homogenous and the anaerobic bacteria, aerobic bacteria, fungi and the like are reproduced by creating a condition for the growth of the microorganisms in the pores. At this time, Propionibacterium As acnes secretes lipase, triglyceride of sebum component changes into free fatty acid. After the hair follicles are densely packed around the hair follicles, the hair follicles are destroyed and the contents of the hair follicles are infiltrated into the dermis and inflammation occurs.
피부에 염증을 유발하는 피부상재균주로 그람 양성균인 Staphylococcus aureus , Staphylococcus. epidermidis 및 Propionibacterium acnes, 효모균 Malassezia furfur 등이 있다. 또한 균주에 의해 두피염과 지루성 피부염, 습진, 비듬, 가려움, 탈모 및 여드름 등도 유발된다. 이런 현상은 생명과는 직접적인 관련이 없으나 개인의 자기평가, 자신감, 자존감 상실, 사람 사이의 관계, 사회적 위치 등의 심리-사회적 영향이 낮게 평가되는 원인이 되고 있어, 심각한 고민거리가 아닐 수 없다. Staphylococcus aureus , Staphylococcus. epidermidis and Propionibacterium acnes , yeast Malassezia and furfur . The strain also causes scalpitis, seborrheic dermatitis, eczema, dandruff, itching, hair loss and acne. This phenomenon is not directly related to life, but it is a serious problem because it causes low psychological-social impacts such as self-evaluation, self-confidence, loss of self-esteem, relationship between people and social position.
현재 염증성 피부질환 치료제로는 스테로이드 제제, 국소 면역억제제, 국소 항생제 및 항히스타민 등이 사용되고 있으나, 상기 약물제제를 장기적으로 사용하는 경우 살이 트는 팽창선조, 피부위축, 모세혈관 확장, 스테로이드성 여드름, 다모증, 자반 등의 부작용이 일어날 수 있다. 특히 스테로이드제를 광범위한 부위에 바르면 피부를 통해 약제가 전신적으로 흡수되어 소아의 경우 성장을 방해할 수 있고, 성인은 골다공증과 같은 전신적인 부작용이 발생할 수 있다. 따라서, 천연물질로부터 유래되어 부작용이 적어 인체에 안전하면서도 염증성 피부질환 개선 효과가 우수한 조성물의 개발이 필요한 실정이다.Currently, steroid preparations, topical immunosuppressants, topical antibiotics, and antihistamines are currently used as therapeutic agents for inflammatory skin diseases. However, when the drug preparation is used for a long period of time, Side effects such as palpitation may occur. In particular, when steroids are applied to a wide range of sites, medication can be systemically absorbed through the skin, which may interfere with growth of the child and systemic side effects such as osteoporosis can occur in adults. Therefore, it is necessary to develop a composition derived from a natural substance, which has few side effects and is safe for the human body and is excellent in an inflammatory skin disease-improving effect.
이에 본 발명자들은 상기한 바와 같이 염증성 피부질환 개선 효과를 가지면서 인체 부작용이 적은 물질을 찾고자 예의 연구한 결과, 상록성 목본식물 추출물 중에서도 담팔수[Elaeocarpus sylvestris var. ellipticus (Thunb.) H. Hara] 추출물 또는 비쭈기나무(Cleyera japonica Thunb.) 추출물이 다른 상록성 목본식물 추출물에 비하여 피부상재균주인 Staphylococcus aureus, Staphylococcus epidermidis, 및 Propionibacterium acnes에 대하여 월등히 향상된 항균 활성을 나타낸다는 사실을 발견함으로써 본 발명을 완성하였다.Therefore, the inventors of the present invention have found that, in order to find a substance having an inflammatory skin disease improving effect and a lesser side effect on human body, the present inventors have found that Elaeocarpus sylvestris var. ellipticus (Thunb.) H. Hara ] extracts or Cleyera japonica Thunb. extract showed significantly improved antimicrobial activity against Staphylococcus aureus, Staphylococcus epidermidis, and Propionibacterium acnes , The present invention has been accomplished by discovering the facts.
선행문헌Precedent literature
대한민국 등록특허 제10-1731794호Korean Patent No. 10-1731794
본 발명은 상록성 목본식물 추출물을 유효성분으로 포함하는 염증성 피부질환의 예방 또는 치료용 약제학적 조성물, 상록성 목본식물 추출물을 포함하는 염증성 피부질환의 개선용 화장료 조성물, 및 상록성 목본식물 추출물을 포함하는 염증성 피부질환의 개선용 건강기능식품을 제공하고자 한다. The present invention relates to a pharmaceutical composition for preventing or treating an inflammatory skin disease comprising an extract of an herbaceous herbaceous plant as an active ingredient, a cosmetic composition for improving inflammatory skin diseases including an herbal botanical extract, and an inflammatory And to provide a health functional food for improving skin diseases.
본 명세서에서 사용된 용어 “항염증”은 염증에 저항하는 것을 의미하는데, 상기 염증은 박테리아, 곰팡이, 바이러스, 다양한 종류의 알레르기 유발물질과 같은 외부 감염원의 침입에 의하여 형성되는 농양의 병리적 상태를 의미한다. As used herein, the term " anti-inflammatory " refers to resistance to inflammation, which is the pathological condition of an abscess formed by the invasion of external infectious agents such as bacteria, fungi, viruses, it means.
본 명세서에서 사용된 용어 "유효성분"이란 단독으로 목적하는 활성을 나타내거나 또는 그 자체는 활성이 없는 담체와 함께 활성을 나타낼 수 있는 성분을 의미한다.The term "active ingredient ", as used herein, refers to a component which alone exhibits the desired activity or which itself can exhibit activity with a carrier that is not active.
본 명세서에서 사용된 용어 "상록성 목본식물"은 추출 방법을 불문하고 추출 대상인 상록성 목본식물 잎, 가지, 뿌리 또는 이들의 혼합물을 메탄올, 에탄올, 부탄올 등의 탄소수 1 내지 5의 알콜, 아세톤, 헥산, 에틸아세테이트, 클로로포름, 디클로로메탄, 물 또는 이들의 혼합 용매로 추출하여 얻어진 추출물과 그 추출물을 상기 열거된 용매로 분획된 추출물을 포함하는 의미로서 이해된다. 추출 방법을 불문하므로, 추출 대상인 상록성 목본식물 잎, 가지, 뿌리 또는 이들의 혼합물을 추출 용매에 침지시키는 단계를 통하여 추출되는 한, 추출 방법은 냉침, 환류, 가온, 초음파 방사 등 임의의 방식이 모두 적용될 수 있는 것으로 이해되어야 한다. 그럼에도 상기 "상록성 목본식물"은 바람직하게는 추출 대상인 상록성 목본식물 잎, 가지, 뿌리 또는 이들의 혼합물을 물, 알코올 또는 이들의 혼합 용매로 추출하고 얻어진 것으로서, 추출 용매가 제거된 농축된 액상의 추출물 또는 고형상의 추출물, 그 고형상의 추출물을 물과 헥산, 물과 디클로로포름, 물과 에틸아세테이트 또는 물과 부탄올로 분획하여 얻어진 어느 한 분획 용매층의 추출물, 또는 그 고형상의 추출물을 물에 현탁한 후, 헥산, 디클로로포름, 에틸아세테이트 및 부탄올을 이용하여 순차적으로 분획하여 얻어진 추출물을 의미한다. 여기서 "순차적으로 분획한다"는 것의 의미는 물층의 분획물을 분획 후에도 계속 사용하여 상기 열거된 순서의 용매로 분획한다는 의미이다.As used herein, the term "unbranched woody plants" refers to leaves, branches, roots, or mixtures thereof of an evergreen woody plant to be extracted, regardless of the extraction method, in an alcohol of 1 to 5 carbon atoms such as methanol, ethanol, butanol, Ethyl acetate, chloroform, dichloromethane, water or a mixed solvent thereof, and an extract obtained by fractionating the extract with the above-listed solvents. As long as it is extracted through the step of immersing the leaves, branches, roots, or a mixture thereof in the extraction solvent, the extraction method may be any method such as freezing, refluxing, heating, It should be understood that the invention can be applied. However, the above-mentioned "evergreen woody plant" is preferably obtained by extracting the leaves, branches, roots or a mixture thereof of water, alcohols or a mixed solvent thereof, which is an extract of concentrated, Or an extract of a solid form, an extract of a fraction solvent layer obtained by fractionating the solid extract with water, hexane, water and dichloroform, water and ethyl acetate or water and butanol, or a solid form of the extract, Followed by suspending, followed by fractionation using hexane, dichloroform, ethyl acetate and butanol. Here, "sequential fractionation" means that the fraction of the water layer is continuously used after fractionation and is fractionated into the solvent of the above-mentioned order.
제1구현예에 따르면, According to a first embodiment,
본 발명은 상록성 목본식물 추출물을 포함하는 염증성 피부질환의 예방 또는 치료용 약제학적 조성물을 제공하고자 하는 것으로, 상기 상록성 목본식물 추출물은 담팔수[Elaeocarpus sylvestris var. ellipticus (Thunb.) H. Hara] 추출물, 비쭈기나무(Cleyera japonica Thunb.) 추출물, 또는 이들의 조합인 것을 특징으로 한다. The present invention provides a pharmaceutical composition for the prevention or treatment of inflammatory skin diseases including an herbaceous plant extract . The extract of the herbaceous herbaceous plant is a plant extract of Elaeocarpus sylvestris var. ellipticus (Thunb.) H. Hara ] extract, Cleyera japonica Thunb. extract, or a combination thereof.
본 발명에 따른 약제학적 조성물에 있어서, 상기 염증성 피부질환은 아토피성 피부염(atopic dermatitis), 접촉성 피부염(contact dermatitis), 지루성 피부염(seborrhea) 및 여드름으로 이루어지는 군으로부터 선택되는 어느 하나일 수 있으나, 이에 제한되는 것은 아니다. In the pharmaceutical composition according to the present invention, the inflammatory skin disease may be any one selected from the group consisting of atopic dermatitis, contact dermatitis, seborrhea and acne, But is not limited thereto.
본 발명에 따른 약제학적 조성물에 있어서, 상기 상록성 목본식물 추출물은 스타피로코쿠스 아우레우스(Staphylococcus aureus ), 스타피로코쿠스 에피더미디스 (Staphylococcus epidermidis ), 및 프로피오니박테리움 아크네스(Propionibacterium acnes)의 활성을 억제시킬 수 있다. In the pharmaceutical compositions according to the invention, the sangrokseong woody plant extracts star fatigue nose kusu aureus (Staphylococcus aureus), star fatigue nose kusu epidermidis (Staphylococcus epidermidis), and propionic sludge tumefaciens arc Ness (Propionibacterium acnes Can be inhibited.
본 발명에 따른 약제학적 조성물에 있어서, 상기 상록성 목본식물 추출물은 상록성 목본식물의 잎 추출물, 가지 추출물 또는 뿌리 추출물일 수 있다. 바람직하기는, 상기 상록성 목본식물 추출물은 상록성 목본식물 잎 추출물이다. In the pharmaceutical composition according to the present invention, the extract of the herbicidal woody plant may be a leaf extract, an eggplant extract or a root extract of an evergreen woody plant. Preferably, the herbaceous plant extract is an evergreen tree leaf extract.
본 발명에 따른 약제학적 조성물에 있어서, 상기 상록성 목본식물 추출물은 상록성 목본식물의 알코올 추출물일 수 있다. 상기 알코올은 탄소수 1 내지 4의 저급 알코올일 수 있다. 예를 들면, 상기 알코올은 메탄올, 에탄올, n-프로판올, iso-프로판올, n-부탄올, iso-부탄올 또는 tert-부탄올일 수 있다. 바람직하기는, 상기 알코올은 메탄올 또는 에탄올일 수 있다. In the pharmaceutical composition according to the present invention, the extract of the herbicidal woody plant may be an alcoholic extract of an evergreen woody plant. The alcohol may be a lower alcohol having 1 to 4 carbon atoms. For example, the alcohol may be methanol, ethanol, n-propanol, iso-propanol, n-butanol, iso-butanol or tert-butanol. Preferably, the alcohol may be methanol or ethanol.
본 발명에 따른 약제학적 조성물에 있어서, 상기 상록성 목본식물 추출물은 상록성 목본식물의 메탄올 추출물을 a) 물과 헥산, 물과 디클로로포름, 물과 에틸아세테이트 또는 물과 부탄올로 분획하여 얻어진 어느 한 분획 용매층의 추출물; 또는 b) 헥산, 디클로로포름, 에틸아세테이트 및 부탄올을 이용하여 순차적으로 분획하여 얻어진 추출물일 수 있다. 바람직하기는, 상기 상록성 목본식물 추출물은 상록성 목본식물의 메탄올 추출물의 부탄올 분획물일 수 있다. In the pharmaceutical composition according to the present invention, the above-mentioned extract of the herbaceous herbaceous plant is obtained by extracting a methanol extract of the herbaceous herbaceous plant in a fraction of water, hexane, water and dichloromethane, water and ethyl acetate or water and butanol Extract of layer; Or b) an extract obtained by successively fractionating using hexane, dichloroform, ethyl acetate and butanol. Preferably, the herbaceous plant extract may be a butanol fraction of a methanol extract of an evergreen tree plant.
본 발명의 약학 조성물은 약학적으로 허용되는 담체를 첨가하여 제제화할 수 있으며, 제제화에 관한 내용은 Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA의 문헌을 참조할 수 있다. 상기 약학적으로 허용 가능한 담체는 의약 발명 부분에 속하는 통상의 기술자에게 의약 조성물 제조시 통상적으로 사용되는 것을 의미한다. 예를 들어, 락토오즈, 덱스트로오즈, 수크로오스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오즈, 메틸 셀룰로오즈, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등이 있다. 또한, 약학적으로 허용되는 담체는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 포함한다.The pharmaceutical composition of the present invention can be formulated by adding a pharmaceutically acceptable carrier. For formulation, refer to Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA. The pharmaceutically acceptable carrier means those conventionally used in the manufacture of a pharmaceutical composition for a person skilled in the art to which the present invention belongs. For example, there may be mentioned lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, Water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. Pharmaceutically acceptable carriers also include diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, and the like.
본 발명의 약학적 조성물에 함유되는 상록성 목본식물 추출물의 적용량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 경우에 따라 적절하게 선택될 수 있다. 예를 들면, 상기 상록성 목본식물 추출물은 1일 0.0001 내지 1000 mg/kg으로, 바람직하게는 0.1 내지 1000 mg/kg의 용량으로 투여될 수 있으며, 상기 적용은 하루에 한번 또는 수회 나누어 적용할 수도 있다. 또한, 상기 약학적 조성물은 조성물 총 중량에 대하여 상기 상록성 목본식물 추출물을 0.0001 내지 50 중량%로 포함할 수 있다. 상기 약학적 조성물은 인간 등의 포유동물에 다양한 경로로, 예를 들면, 경피, 경구, 정맥, 근육, 또는 피하 주사에 의해 적용될 수 있다.The amount of the herbicidal extract of the herbaceous plant contained in the pharmaceutical composition of the present invention varies depending on the condition and body weight of the patient, the severity of the disease, the drug form, the administration route and the period, but may be appropriately selected depending on the case. For example, the herbicidal extract of the herbicide may be administered at a dose of 0.0001 to 1000 mg / kg per day, preferably 0.1 to 1000 mg / kg per day, and the application may be applied once a day or divided into several times . In addition, the pharmaceutical composition may contain 0.0001 to 50% by weight of the above-mentioned non-specific woody plant extract, based on the total weight of the composition. The pharmaceutical composition may be applied to mammals such as humans by various routes, for example, transdermal, oral, intravenous, intramuscular, or subcutaneous injection.
본 발명의 약학적 조성물은 상록성 목본식물 추출물 외에 피부 염증의 개선, 완화, 치료 또는 예방을 나타내는 유효성분을 1종 이상 함유할 수 있다.The pharmaceutical composition of the present invention may contain at least one active ingredient which exhibits improvement, alleviation, treatment or prevention of skin inflammation in addition to the extract of the herbicide of woody plants.
본 발명의 약학적 조성물은 피부 염증의 개선, 완화, 치료 또는 예방을 위하여 단독으로, 또는 수술, 호르몬 치료, 약물 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.The pharmaceutical composition of the present invention can be used alone, for improving, alleviating, treating or preventing skin inflammation, or in combination with methods using surgery, hormone therapy, drug therapy and biological response modifiers.
제2구현예에 따르면, According to a second embodiment,
본 발명은 상록성 목본식물 추출물을 포함하는 염증성 피부질환의 개선용 화장료 조성물을 제공하고자 하는 것으로, 상기 상록성 목본식물 추출물은 담팔수[Elaeocarpus sylvestris var. ellipticus (Thunb.) H. Hara] 추출물, 비쭈기나무(Cleyera japonica Thunb.) 추출물, 또는 이들의 조합인 것을 특징으로 한다. The present invention provides a cosmetic composition for improving inflammatory skin diseases, which comprises an extract of an herbaceous herbaceous plant, wherein the herbaceous plant extract of Eucalyptus is Elaeocarpus sylvestris var. ellipticus (Thunb.) H. Hara ] extract, Cleyera japonica Thunb. extract, or a combination thereof.
본 발명에 따른 화장료 조성물에 있어서, 상기 염증성 피부질환은 아토피성 피부염(atopic dermatitis), 접촉성 피부염(contact dermatitis), 지루성 피부염(seborrhea) 및 여드름으로 이루어지는 군으로부터 선택되는 어느 하나일 수 있으나, 이에 제한되는 것은 아니다. In the cosmetic composition according to the present invention, the inflammatory skin disease may be any one selected from the group consisting of atopic dermatitis, contact dermatitis, seborrhea and acne, But is not limited to.
본 발명에 따른 화장료 조성물에 있어서, 상기 상록성 목본식물 추출물은 스타피로코쿠스 아우레우스(Staphylococcus aureus ), 스타피로코쿠스 에피더미디스 (Staphylococcus epidermidis ), 및 프로피오니박테리움 아크네스(Propionibacterium acnes)의 활성을 억제시킬 수 있다. In the cosmetic composition according to the present invention, the sangrokseong woody plant extracts star fatigue nose kusu aureus (Staphylococcus aureus), star fatigue nose kusu epidermidis (Staphylococcus epidermidis), and propionic sludge tumefaciens arc Ness (Propionibacterium acnes) Can be inhibited.
본 발명에 따른 화장료 조성물에 있어서, 상기 상록성 목본식물 추출물은 상록성 목본식물의 잎 추출물, 가지 추출물 또는 뿌리 추출물일 수 있다. 바람직하기는, 상기 상록성 목본식물 추출물은 상록성 목본식물 잎 추출물이다. In the cosmetic composition according to the present invention, the extract of the herbicide of the present invention may be a leaf extract, an eggplant extract or a root extract of an evergreen woody plant. Preferably, the herbaceous plant extract is an evergreen tree leaf extract.
본 발명에 따른 화장료 조성물에 있어서, 상기 상록성 목본식물 추출물은 상록성 목본식물의 알코올 추출물일 수 있다. 상기 알코올은 탄소수 1 내지 4의 저급 알코올일 수 있다. 예를 들면, 상기 알코올은 메탄올, 에탄올, n-프로판올, iso-프로판올, n-부탄올, iso-부탄올 또는 tert-부탄올일 수 있다. 바람직하기는, 상기 알코올은 메탄올 또는 에탄올일 수 있다. In the cosmetic composition according to the present invention, the extract of the herbicidal woody plant may be an alcoholic extract of an evergreen woody plant. The alcohol may be a lower alcohol having 1 to 4 carbon atoms. For example, the alcohol may be methanol, ethanol, n-propanol, iso-propanol, n-butanol, iso-butanol or tert-butanol. Preferably, the alcohol may be methanol or ethanol.
본 발명에 따른 화장료 조성물에 있어서, 상기 상록성 목본식물 추출물은 상록성 목본식물의 메탄올 추출물을 a) 물과 헥산, 물과 디클로로포름, 물과 에틸아세테이트 또는 물과 부탄올로 분획하여 얻어진 어느 한 분획 용매층의 추출물; 또는 b) 헥산, 디클로로포름, 에틸아세테이트 및 부탄올을 이용하여 순차적으로 분획하여 얻어진 추출물일 수 있다. 바람직하기는, 상기 상록성 목본식물 추출물은 상록성 목본식물의 메탄올 추출물의 부탄올 분획물일 수 있다. In the cosmetic composition according to the present invention, the above-mentioned extract of the herbaceous herbaceous plant is obtained by extracting a methanol extract of an evergreen woody plant with a) one fraction solvent layer obtained by fractionating water with hexane, water and dichloroform, water and ethyl acetate or water and butanol ≪ / RTI > Or b) an extract obtained by successively fractionating using hexane, dichloroform, ethyl acetate and butanol. Preferably, the herbaceous plant extract may be a butanol fraction of a methanol extract of an evergreen tree plant.
본 발명의 화장료 조성물은 유연화장수, 수렴화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 아이크림, 아이에센스, 클렌징크림, 클렌징폼, 클렌징워터, 팩, 파우더, 바디로션, 바디크림, 바디오일, 바디에센스, 메이크업 베이스, 파운데이션, 염모제, 샴푸, 린스 및 바디 세정제로 이루어지는 군으로부터 선택되는 제형 일 수 있다.The cosmetic composition of the present invention can be used as a cosmetic composition for cosmetics such as softening lotion, convergent lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, pack, powder, body lotion, , A body essence, a makeup base, a foundation, a hair dye, a shampoo, a rinse and a body cleanser.
본 발명의 화장료 조성물은 상기 상록성 목본식물 추출물을 사용하여 통상의 화장료 제조방법에 따라, 다양한 형태로 제조될 수 있으며, 화장료 조성물 분야에서 통상적으로 사용되는 안정화제, 용해화제, 비타민, 안료, 및 향료와 같은 통상적인 보조제를 포함할 수 있다. 또한, 화장료 조성물이 상기 고사리삼 알코올 추출물을 함유하는 향장 제품, 샴푸, 헤어로션, 헤어크림, 헤어젤 등의 형태로 제조될 경우, 통상의 클렌징액, 수렴액 및 보습액으로 희석하여 사용될 수 있다. 본 발명의 화장료 조성물은 특히 화장수, 로션, 크림, 에센스 형태로 제조되는 것이 바람직하다.The cosmetic composition of the present invention can be prepared in various forms according to a conventional cosmetic preparation method using the above-mentioned extract of the herbaceous woody plant, and can be used as a stabilizer, a dissolving agent, a vitamin, a pigment, , ≪ / RTI > and the like. When the cosmetic composition is prepared in the form of a perfumed product containing the gosaricin alcohol extract, a shampoo, a hair lotion, a hair cream, a hair gel, etc., it can be diluted with a usual cleansing solution, a converging solution and a moisturizing solution. The cosmetic composition of the present invention is particularly preferably prepared in the form of a lotion, lotion, cream, or essence.
본 발명의 화장료 조성물에서 상록성 목본식물 추출물은 화장료 조성물의 총 액상 중량에 대하여 0.1중량%~10중량%의 양으로 화장료에 첨가될 수 있고, 또한 화장료 조성물의 총 건조중량에 대하여 0.001∼5중량%, 바람직하게는 0.01∼3중량%의 양으로 화장료에 첨가될 수 있다.In the cosmetic composition of the present invention, the extract of the herbicide of the present invention may be added to the cosmetic composition in an amount of 0.1 to 10 wt% based on the total weight of the cosmetic composition, and may be added in an amount of 0.001 to 5 wt% , Preferably 0.01 to 3% by weight, based on the total weight of the cosmetic composition.
제3구현예에 따르면, According to a third embodiment,
본 발명은 상록성 목본식물 추출물을 포함하는 염증성 피부질환의 개선용 식품 조성물을 제공하고자 하는 것으로, 상기 상록성 목본식물 추출물은 담팔수[Elaeocarpus sylvestris var. ellipticus (Thunb.) H. Hara] 추출물, 비쭈기나무(Cleyera japonica Thunb.) 추출물, 또는 이들의 조합인 것을 특징으로 한다. The present invention provides a food composition for improving inflammatory skin diseases, which comprises an extract of a herbaceous herbaceous plant. The herbaceous plant extract of the present invention can be used as an extract of Elaeocarpus sylvestris var. ellipticus (Thunb.) H. Hara ] extract, Cleyera japonica Thunb. extract, or a combination thereof.
본 발명에 따른 식품 조성물에 있어서, 상기 염증성 피부질환은 아토피성 피부염(atopic dermatitis), 접촉성 피부염(contact dermatitis), 지루성 피부염(seborrhea) 및 여드름으로 이루어지는 군으로부터 선택되는 어느 하나일 수 있으나, 이에 제한되는 것은 아니다. In the food composition according to the present invention, the inflammatory skin disease may be any one selected from the group consisting of atopic dermatitis, contact dermatitis, seborrhea and acne, But is not limited to.
본 발명에 따른 식품 조성물에 있어서, 상기 상록성 목본식물 추출물은 스타피로코쿠스 아우레우스(Staphylococcus aureus ), 스타피로코쿠스 에피더미디스 (Staphylococcus epidermidis ), 및 프로피오니박테리움 아크네스(Propionibacterium acnes)의 활성을 억제시킬 수 있다. In the food composition according to the invention, the sangrokseong woody plant extracts star fatigue nose kusu aureus (Staphylococcus aureus), star fatigue nose kusu epidermidis (Staphylococcus epidermidis), and propionic sludge tumefaciens arc Ness (Propionibacterium acnes) Can be inhibited.
본 발명에 따른 건강기능식품에 있어서, 상기 상록성 목본식물 추출물은 상록성 목본식물의 잎 추출물, 가지 추출물 또는 뿌리 추출물일 수 있다. 바람직하기는, 상기 상록성 목본식물 추출물은 상록성 목본식물 잎 추출물이다. In the health functional food according to the present invention, the above-mentioned non-specific woody plant extract may be a leaf extract, an eggplant extract or a root extract of an evergreen woody plant. Preferably, the herbaceous plant extract is an evergreen tree leaf extract.
본 발명에 따른 건강기능식품에 있어서, 상기 상록성 목본식물 추출물은 상록성 목본식물의 알코올 추출물일 수 있다. 상기 알코올은 탄소수 1 내지 4의 저급 알코올일 수 있다. 예를 들면, 상기 알코올은 메탄올, 에탄올, n-프로판올, iso-프로판올, n-부탄올, iso-부탄올 또는 tert-부탄올일 수 있다. 바람직하기는, 상기 알코올은 메탄올 또는 에탄올일 수 있다. In the health functional food according to the present invention, the extract of the herbicidal woody plant may be an alcoholic extract of the herbaceous woody plant. The alcohol may be a lower alcohol having 1 to 4 carbon atoms. For example, the alcohol may be methanol, ethanol, n-propanol, iso-propanol, n-butanol, iso-butanol or tert-butanol. Preferably, the alcohol may be methanol or ethanol.
본 발명에 따른 건강기능식품에 있어서, 상기 상록성 목본식물 추출물은 상록성 목본식물의 메탄올 추출물을 a) 물과 헥산, 물과 디클로로포름, 물과 에틸아세테이트 또는 물과 부탄올로 분획하여 얻어진 어느 한 분획 용매층의 추출물; 또는 b) 헥산, 디클로로포름, 에틸아세테이트 및 부탄올을 이용하여 순차적으로 분획하여 얻어진 추출물일 수 있다. 바람직하기는, 상기 상록성 목본식물 추출물은 상록성 목본식물의 메탄올 추출물을의 부탄올 분획물일 수 있다. In the health functional food according to the present invention, the abovementioned extract of the herbaceous herbaceous plant is obtained by extracting a methanol extract of an herbaceous herbaceous plant in a fraction of water, hexane, water and dichloromethane, water and ethyl acetate or water and butanol, Extract of layer; Or b) an extract obtained by successively fractionating using hexane, dichloroform, ethyl acetate and butanol. Preferably, the herbaceous plant extract may be a butanol fraction of a methanol extract of an evergreen woody plant.
본 발명의 건강기능식품은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있고, 그 밖에 천연 과일쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다.The health functional food of the present invention can be used as a nutritive, a vitamin, a mineral (electrolyte), a flavoring agent such as a synthetic flavor agent and a natural flavor agent, a coloring agent and an aging agent (cheese, chocolate etc.), a pectic acid and its salt, A salt, an organic acid, a protective colloid thickener, a pH adjusting agent, a stabilizer, a preservative, a glycerin, an alcohol, a carbonating agent used in a carbonated beverage, and the like, as well as the production of natural fruit juice and fruit juice drinks and vegetable drinks ≪ / RTI > These components may be used independently or in combination.
본 발명의 건강기능식품은 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 껌류, 아이스크림류, 스프, 음료수, 차, 기능수, 드링크제, 알콜 음료 및 비타민 복합제 중 어느 하나의 형태일 수 있다.The health functional food of the present invention may be any one of meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, gum, ice cream, soup, beverage, tea, functional water, Lt; / RTI >
본 발명의 건강기능식품은 식품첨가물을 추가로 포함할 수 있으며, "식품첨가물"로서의 적합여부는 다른 규정이 없는 한 식품의약품안전청에 승인된 식품첨가물공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다. 상기 "식품첨가물공전"에 수재된 품목으로 예를 들어, 케톤류, 글리신, 구연산칼륨, 니코틴산, 계피산 등의 화학적 합성품, 감색소, 감초추출물, 결정셀롤로오스, 고랭색소, 구아검 등의 천연첨가물, L-글루타민산나트륨제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합 제제류들을 들 수 있다.The health functional food of the present invention may further contain food additives and the suitability of the food additives as "food additives" is to be determined in accordance with the General Rules and General Test Methods approved by the Food and Drug Administration, Shall be determined according to the relevant standards and standards. Examples of the products listed in the above-mentioned "food additives" include natural products such as ketones, chemical products such as glycine, potassium citrate, nicotinic acid and cinnamic acid, coloring matter, licorice extract, crystalline cellulosic, high- , A sodium L-glutamate preparation, a noodle-added alkaline agent, a preservative preparation, a tar coloring agent, and the like.
본 발명의 건강기능식품을 제조하는 과정에서 음료를 포함한 식품에 첨가되는 본 발명의 상록성 목본식물 추출물은 필요에 따라 그 함량을 적절히 가감할 수 있으며, 바람직하게는 전체 식품 100 중량%에 대하여 1 내지 15 중량% 포함되도록 첨가하는 것이 바람직하다.The content of the extract of the herbicidal woody plant of the present invention added to foods containing beverages in the process of producing the health functional food of the present invention can be appropriately increased or decreased, By weight to 15% by weight.
본 발명의 상록성 목본식물 추출물, 예를 들면 담팔수[Elaeocarpus sylvestris var. ellipticus (Thunb.) H. Hara] 추출물, 비쭈기나무(Cleyera japonica Thunb.) 추출물, 또는 이들의 조합은 스타피로코쿠스 아우레우스(Staphylococcus aureus), 스타피로코쿠스 에피더미디스 (Staphylococcus epidermidis), 및 프로피오니박테리움 아크네스(Propionibacterium acnes)의 활성을 저해함으로써 다양한 피부염증반응에 대한 항염증 효능을 가진다. 따라서, 상기 담팔수 추출물, 비쭈기나무 추출물, 또는 이들의 조합은 세포 독성 및 피부 부작용이 없어 약제학적 조성물, 화장료 조성물 및 건강기능식품에 안전하게 사용할 수 있다.The herbaceous plant extracts of the present invention, such as Elaeocarpus sylvestris var. The extract, the Cleyera japonica Thunb. extract, or a combination thereof may be selected from the group consisting of Staphylococcus aureus , Staphylococcus epidermidis , Staphylococcus epidermidis , And Propionibacterium acnes , thereby having an anti-inflammatory effect against various skin inflammation reactions. Accordingly, the descendant water extract, the sour chestnut extract, or a combination thereof can be used safely in pharmaceutical compositions, cosmetic compositions and health functional foods because of no cytotoxicity and skin side effects.
이하에서는 본 발명을 실시예에 의하여 더욱 상세히 설명한다. 그러나, 본 발명이 이하의 실시예에 의하여 한정되는 것은 아니다. Hereinafter, the present invention will be described in more detail by way of examples. However, the present invention is not limited by the following examples.
재료 및 방법Materials and methods
1. 실험 재료1. Experimental material
담팔수[Elaeocarpus sylvestris var. ellipticus (Thunb.) H. Hara] 및 비쭈기나무(Cleyera japonica Thunb.)의 잎과 가지를 제주도 일대에서 채취한 후, 동결건조기(freeze dryer FD8512, Ilsin, Korea)를 이용하여 48시간 동안 동결건조 하였다. 건조된 시료는 분쇄기(Hood mixer FM-681C, Hanil, Korea)로 곱게 분쇄한 후, -70±2℃의 deep freezer(Ultra-low temperature freezer SW-U5-200, Samwon, Korea)에 저장하여 사용하였다. Elaeocarpus sylvestris var. Leaves and branches of ellipticus (Thunb.) H. Hara and Cleyera japonica Thunb. were collected from Jeju Island and lyophilized for 48 hours using a freeze dryer (FD8512, Ilsin, Korea) . The dried samples were finely pulverized with a grinder (Hood mixer FM-681C, Hanil, Korea) and stored in a deep freezer (Ultra-low temperature freezer SW-U5-200, Samwon, Korea) at -70 ± 2 ℃ Respectively.
2. 초음파 추출2. Ultrasonic Extraction
초음파 추출은 30×24×14.5cm 크기의 ultrasonic cleaner(5510-DTH, Bransonic, USA)를 이용하여 시행하였다. 건조시료 1g과 용매를 유리병에 넣어 혼합한 후 아크릴판에 부착하였으며 초음파 수조 내부에 5L의 물을 넣어 하단으로부터 약 9cm 높이로 물을 채운 후 30분 동안 추출하였다. 추출 당시 초음파 수조 내 수온은 20±2℃ 이었으며, 추출 15분 후에는 1.0±0.5℃, 30분 후에는 2.5±0.8℃, 45분 후에는 3.6±0.7℃ 상승하였다. 모든 추출물은 잔사를 재추출하지 않고 1회 추출하였으며, 추출의 정확성을 더하기 위하여 2반복 추출하였다. 추출이 끝난 후 바로 여과지(Advantec No. 2, Toyo Roshi Kaisha Ltd., Japan)를 사용하여 vacuum pump(GAST)로 감압여과 하였으며, 여과된 추출물은 용매를 이용하여 최종 농도를 50배로 정량하였다. 한 종류의 건조시료에서 얻어진 2개의 추출물로부터 5mL씩 증발접시에 담아 60±2℃의 dry oven(KPI-507L, Korea Power Ind. Co. Ltd, Korea)에 2일 이상 건조시킨 후 데시케이터에서 수분을 제거하여 추출물의 가용성 고형분 함량(g·g-1 db)을 구하였다. 남은 추출물은 혼합 후 질소 충전하여 -70℃(SW-UF-200, Samwon Engineering Co., Korea)에 보관하면서 실험에 사용하였다. Ultrasonography was performed using a 30 × 24 × 14.5 cm ultrasonic cleaner (5510-DTH, Bransonic, USA). 1 g of the dry sample and solvent were mixed in a glass bottle and attached to an acrylic plate. 5 L of water was added to the inside of the ultrasonic bath, and the mixture was filled with water at a height of about 9 cm from the bottom and then extracted for 30 minutes. The water temperature in the ultrasonic bath at the time of extraction was 20 ± 2 ℃, and it was 1.0 ± 0.5 ℃ after 15 minutes, 2.5 ± 0.8 ℃ after 30 minutes and 3.6 ± 0.7 ℃ after 45 minutes. All extracts were extracted once without re-extracting the residues, and extracted twice to add accuracy of extraction. After the extraction, the filtrate was filtered through a vacuum pump (GAST) using a filter paper (Advantec No. 2, Toyo Roshi Kaisha Ltd., Japan), and the final concentration of the filtered extract was determined to be 50 times by using a solvent. After drying for 2 days or more in a dry oven (KPI-507L, Korea Power Ind. Co., Ltd., Korea) at 60 ± 2 ° C in 5 mL of evaporation dish from 2 kinds of extracts obtained from one kind of dry sample, The water content was removed to obtain a soluble solid content (g · g-1 db) of the extract. The remaining extracts were mixed with nitrogen and stored at -70 ° C (SW-UF-200, Samwon Engineering Co., Korea).
3. 균주 재료3. Strain material
추출물의 항균활성을 측정하기 위하여 실험에 사용된 균주는 피부에 염증을 유발할 수 있는 피부유해세균으로 그람 양성균인 Staphylococcus aureaus (KCTC 1927), Staphylococcus epidermidis (KCTC 1917) 및 Propionibacterium acnes(KCTC 3320) 3종을 선정하여 한국유전자 은행에서 분양받아 사용하였다. In order to measure the antimicrobial activity of the extracts, the strains used in the experiment were skin-harmful bacteria that could cause skin inflammation, and Staphylococcus aureaus (KCTC 1927), Staphylococcus epidermidis ( KCTC 1917) and Propionibacterium acnes (KCTC 3320) were purchased from the Korean Gene Bank.
4. 배양환경 및 생육특성4. Culture environment and growth characteristics
(1) 배양 환경(1) Culture environment
실험에 사용한 미생물 배양에 사용한 배지는 Mueller Hinton(275730, Difco Laboratories, USA) 및 RCM broth(Reinforced Clostridial Medium, Difco, USA)이며, 미생물은 모두 37℃에서 배양하였다(표 1). 3∼5주 간격으로 계대배양 하던 미생물을 실험 2주 전부터 3∼5일 간격으로 broth 10mL에 미생물 배양액 100μL를 접종하여 활성화시켜 사용하였다. 혐기성 세균인 P. acnes는 agar broth에 배양하여 gas pak(AnaeroPack®, Mitsubishi Gas Chemical Co., Inc, Japan)을 넣은 밀폐용기에 넣어 37℃의 CO2 incubator(VS-9108MS, Vision, Korea)에서 배양하던 균주를 사용하였다. The medium used for the microbiological culture was Mueller Hinton (275730, Difco Laboratories, USA) and RCM broth (Reinforced Clostridial Medium, Difco, USA). All microorganisms were cultured at 37 ℃ (Table 1). The microorganisms that were subcultured at intervals of 3 to 5 weeks were inoculated with 100 μL of microbial culture in 10 mL of broth at intervals of 3 to 5 days two weeks before the experiment. P. acnes , an anaerobic bacterium, was cultured in agar broth and placed in a sealed container containing gas pak (AnaeroPack ® , Mitsubishi Gas Chemical Co., Inc, Japan) and incubated at 37 ° C in a CO 2 incubator (VS-9108MS, Vision, The strain that was cultured was used.
[표 1][Table 1]
zRCM broth(Reinforced Clostridial), M-H broth(Mueller Hinton) z RCM broth (Reinforced Clostridial), MH broth (Mueller Hinton)
2) 생장곡선 및 생균수2) Growth curve and number of living cells
실험에 사용한 미생물의 생장곡선과 생균수를 측정하여 생육특성을 파악하였다. 미리 활성화 시킨 미생물을 visible spectrophotometer(NovaspecTM Plus, Biochrom, England)를 이용하여 650nm에서 optimal density(O.D.)가 1.0이 되도록 조절하였다. 96 well-plate(96 cell culture well plate; F-type, SPL, Korea)에 broth 100μL, O.D.를 1.0으로 조절한 미생물 배양액 100μL를 Multichannel pippet (Transferpette®-8, Brand, Germany)으로 broth와 배양액을 고르게 섞어준 다음 37℃의 incubator에서 48시간 동안 배양하면서 4시간 간격으로 생장곡선을 측정하였다. Growth curves and microbial counts of the microorganisms used in the experiments were measured to determine the growth characteristics. Preactivated microorganisms were adjusted to an optimal density (OD) of 1.0 at 650 nm using a visible spectrophotometer (Novaspec ™ Plus, Biochrom, England). 100 μL of broth and OD of 1.0 were added to a 96-well plate (96-cell culture plate; F-type, SPL, Korea) with a Multichannel pipette (Transferpette ® -8, Brand, Germany) And then the growth curve was measured at intervals of 4 hours while culturing in an incubator at 37 ° C. for 48 hours.
실험 18시간 전에 10mL의 broth에 10μL의 배양균을 접종하여 활성화 시킨 후, 실험 직전에 650nm에서 O.D를 1.0으로 조절하여 생균수를 측정하였다. Agar 1.5%를 첨가한 broth를 90×15mm plate(Petri dish, Green Cross Corp., Korea)에 12mL씩 분주하여 clean bench 내에서 미리 굳혔다. O.D 1.0의 미생물 배양액은 희석하여, 농도별로 3반복씩 agar broth 위에 100μL를 분주하여 spreader(Spreade; 90050, SPL, Korea)로 고르게 편 후, 24시간 후에 형성된 colony를 세어 생균수를 확인하였다. 단, P. acnes 실험구는 48시간 후에 생균수를 조사하였다. 18 hours before the experiment, 10 mL of culture was inoculated into 10 mL of broth and activated, and OD was adjusted to 1.0 at 650 nm immediately before the experiment to measure viable cells. Broth containing 1.5% Agar was dispensed in a volume of 12 mL onto a 90 × 15 mm plate (Petri dish, Green Cross Corp., Korea) and pre-hardened in a clean bench. The culture broth of OD 1.0 was diluted, and 100 μL of the agar broth was divided into 3 replicates for each concentration. After spreading to a spreader (Spreade; 90050, SPL, Korea), colony formed after 24 hours was counted. However, P. acnes The number of viable cells was examined 48 hours after the experiment.
5. Agar diffusion법을 이용한 추출물의 항균활성5. Antimicrobial activity of extracts by agar diffusion method
질소가스를 충진하여 -70℃에서 저장 중이던 메탄올 추출물은 감압농축한 다음 DMSO로 녹여 가용성 고형분의 농도가 50mg·mL-1이 되도록 조절하였다. 50mg·mL-1 농도의 추출물은 clean bench 내에서 멸균한 8mm의 disc(Filter paper, Advantec Toyo Roshi International Inc., Japan)에 40μL 주입하여 2mg/disc가 되도록 하였다. 주입 후 건조하여 용매가 충분히 휘발되도록 하였다. The methanol extract, which was stored at -70 ° C by filling with nitrogen gas, was concentrated under reduced pressure and then dissolved in DMSO to adjust the concentration of soluble solid to 50 mg · mL -1 . The extract of 50mg · mL- 1 concentration was injected 40μL into an 8mm disc (Filter paper, Advantec Toyo Roshi International Inc., Japan) sterilized in a clean bench to be 2mg / disc. After the injection, it was dried to sufficiently volatilize the solvent.
0.7%의 agar를 첨가한 soft agar broth는 121℃ 1.2기압에서 15분 동안 멸균한 다음 항온수조에서 agar broth의 온도가 60℃가 되도록 조절하였다. 미리 활성화 시킨 미생물 배양액은 O.D.를 1.0으로 조절하여 60℃의 soft agar broth에 1% v/v로 접종하였다. 미생물 배양액을 접종한 후, magnetic stirrer로 고르게 섞어주었으며, 바로 90×15mm의 plate에 agar broth를 12mL씩 분주하였다. 미생물을 넣은 soft agar broth는 plate에 분주한 후 clean bench내에서 굳혔으며, 분주 후 15분 이내에 추출물을 주입한 disc를 치상하였다. 추출물의 배지 내 침투를 용이하게 하기 위하여 4℃의 냉장고에서 1시간 동안 배양한 후, 37℃의 incubator로 옮겨 24시간 동안 배양하였으며, 배양 후 8mm disc의 직경을 포함한 clear zone을 측정하였다. 추출물의 항균활성을 비교하기 위하여 항균물질인 추출물의 항균력을 비교하기 위해 합성항균제인 phenoxyethanol(0H2108, Junsei Chemical Co., Ltd., Japan), methylparaben (8K5015, Junsei Chemical Co., Ltd., Japan)을 0.4, 1, 2, 4mg/disc의 농도로 희석하여 추출물과 같은 조건으로 배양하여 항균력을 비교하였다. The soft agar broth containing 0.7% agar was sterilized at 121 ° C and 1.2 atm for 15 min, and then the temperature of agar broth was adjusted to 60 ° C in a constant temperature water bath. The pre-activated microbial cultures were inoculated at 1% v / v in soft agar broth at 60 ° C with OD adjusted to 1.0. After inoculating the microbial culture, the mixture was evenly mixed with a magnetic stirrer, and 12 mL of agar broth was dispensed into a 90 × 15 mm plate. The soft agar broth containing microorganisms was blotted on a plate and solidified in a clean bench. The discs were infused with extracts within 15 minutes after dispensing. To facilitate the penetration of the extract into the medium, the cells were incubated in a refrigerator at 4 ° C for 1 hour, transferred to an incubator at 37 ° C for 24 hours, and the clear zone including the diameter of the 8 mm disc was measured after culturing. To compare the antimicrobial activity of the extracts, phenoxyethanol (0H2108, Junsei Chemical Co., Ltd., Japan), methylparaben (8K5015, Junsei Chemical Co., Ltd., Japan) Were diluted to 0.4, 1, 2, and 4 mg / disc and cultured under the same conditions as the extracts.
6. 통계 분석6. Statistical Analysis
Agar diffusion법을 이용한 항균활성 분석은 3반복, 추출물의 농도 및 배양시간에 따른 항균활성 분석은 6반복을 1회로 2회 반복 실험하였다. 실험 후 모든 결과값은 SAS version 9.3(SAS instritute Inc., Cary, NC, USA)를 이용하여 평균과 표준오차를 구하였으며, p<0.05의 유의수준에서 Duncan's multiple range test를 이용하여 통계분석 하였다. 또한 추출조건에 따른 항균활성에서는 추출부위, 용매 및 시간 간의 요인별 유의성 검정을 실시하였다.The antimicrobial activity analysis by Agar diffusion method was repeated three times, and the analysis of antimicrobial activity by the concentration of extract and incubation time was repeated 6 times for 1 time twice. The mean and standard errors were calculated using SAS version 9.3 (SAS Instruute Inc., Cary, NC, USA) and statistical analysis was performed using Duncan's multiple range test at a significance level of p <0.05. For the antimicrobial activity according to the extraction conditions, the significance test was performed for each factor between extraction site, solvent and time.
<실시예><Examples>
실시예 1: 피부상재균에 대한 항균 활성Example 1: Antimicrobial activity against dermatophytes
1-1. Staphylococcus aureaus에 대한 항균 활성 1-1. Antibacterial activity against Staphylococcus aureaus
피부 유해균으로 알려진 Staphylococcus aureaus(KCTC 1927)의 억제활성에 미치는 담팔수 및 비쭈기나무 메탄올 추출물의 영향을 agar diffusion법으로 분석하였다. 담팔수 및 비쭈기나무의 잎과 가지 동결건조 시료 1g을 100% 메탄올(methanol, Merck, Germany)을 용매로 30분 동안 초음파 추출하여 얻어진 추출물을 실험에 사용하였다. 담팔수 및 비쭈기나무의 잎과 가지 추출물은 가용성 고형분의 농도를 50mg·mL-1의 농도로 일정하게 조절하여 agar diffusion 방법을 이용하여 2mg/disc 농도에서의 항균력을 확인하고 그 결과를 하기의 표 2에 나타내었다. 한편, 대조구로서 합성 항균제인 methylparaben과 phenoxyethanol을 0.4, 1.0, 2.0, 및 4.0mg/disc의 농도에서 사용하였다. The effect of methanol extracts from the paddy field and bamboo shoots on the inhibitory activity of Staphylococcus aureaus (KCTC 1927), known as skin harmful bacteria, was analyzed by agar diffusion method. The extracts obtained by ultrasonication of 1 g of lyophilized and untrimmed leaves and branches with 100% methanol (Merck, Germany) in a solvent for 30 minutes were used in the experiment. The antimicrobial activity at 2 mg / disc concentration was confirmed using an agar diffusion method by adjusting the concentration of soluble solids to a concentration of 50 mg · mL-1, and the results are shown in Table 2 below Respectively. As a control, methylparaben and phenoxyethanol were used as synthetic antibiotics at the concentrations of 0.4, 1.0, 2.0, and 4.0 mg / disc.
[표 2][Table 2]
상기 표 2로부터 알 수 있듯이, 담팔수(2mg/disc, 23.30mm) 및 비쭈기나무(2mg/disc, 18.95mm)의 잎 추출물의 경우 대조구인 4mg/disc 농도의 methylparaben(13.80mm) 및 4mg/disc 농도의 phenoxyethanol(9.80mm) 보다 현저히 우수한 억제 활성을 갖는 것으로 확인되었다.As can be seen from Table 2, methylparaben (13.80mm) and 4mg / disc concentrations of control (4mg / disc) were used as controls for leaves extracts of 2mg / disc and 23.30mm and 2, Of phenoxyethanol (9.80 mm).
1-2. Staphylococcus epidermidis에 대한 항균 활성 1-2. Antibacterial activity against Staphylococcus epidermidis
피부 유해균으로 알려진 Staphylococcus epidermidis(KCTC 1917)의 억제활성에 미치는 담팔수 및 비쭈기나무의 잎과 가지 메탄올 추출물의 영향을 상기와 동일한 방법으로 알아보고, 그 결과를 하기의 표 3에 나타내었다. The effects of methanol extracts of leaves and branches on the moth and elk trees and on the inhibitory activity of Staphylococcus epidermidis ( KCTC 1917), which is known as skin noxious bacteria, were examined in the same manner as above, and the results are shown in Table 3 below.
[표 3][Table 3]
상기 표 3으로부터 알 수 있듯이, 담팔수(2mg/disc, 17.60mm) 및 비쭈기나무(2mg/disc, 19.25mm)의 잎 추출물의 경우 대조구인 methylparaben(2mg/disc, 15.20mm) 및 phenoxyethanol(2mg/disc, 16.30mm) 보다 우수한 억제 활성을 갖는 것으로 나타났다. As can be seen from Table 3, in the case of leaves extract of 2 mg / disc, 17.60 mm and 2 mg / disc, 19.25 mm, methylparaben (2 mg / disc, 15.20 mm) and phenoxyethanol , 16.30 mm).
1-3. Propionibacterium acnes에 대한 항균 활성 1-3. Antibacterial activity against Propionibacterium acnes
피부 유해균으로 알려진 Propionibacterium acnes(KCTC 3320)의 억제활성에 미치는 담팔수 및 비쭈기나무의 잎 메탄올 추출물의 영향을 상기와 동일한 방법으로 알아보고, 그 결과를 하기의 표 4에 나타내었다. Propionibacterium The effect of the methanol extract of the leaves of the pine trees and the tsukkii on the inhibitory activity of acnes (KCTC 3320) was investigated in the same manner as above, and the results are shown in Table 4 below.
[표 4][Table 4]
상기 표 4로부터 알 수 있듯이, 담팔수(2mg/disc, 27.10mm) 및 비쭈기나무(2mg/disc, 28.50mm)의 잎 추출물의 경우 대조구인 methylparaben(2mg/disc, 24.70mm) 및 phenoxyethanol(2mg/disc, 13.40mm) 보다 현저히 우수한 억제 활성을 갖는 것으로 나타났다. As can be seen from Table 4, in the case of leaves extract of 2 mg / disc, 27.10 mm and 27.2 mm, methylparaben (2 mg / disc, 24.70 mm) and phenoxyethanol (2 mg / disc, , 13.40 mm).
실시예 2. 추출 조건에 따른 항균활성 비교Example 2. Comparison of antibacterial activities according to extraction conditions
2-1. 담팔수의 추출 조건에 따른 항균 활성2-1. Antibacterial activity according to extraction conditions
추출조건에 따른 항균활성실험은 100% 메탄올을 용매로 사용하여 초음파 추출한 조추출물 및 피부 유해균으로서 Staphylococcus aureaus을 이용하여 수행하였다. 추출용매 및 추출시간에 따른 항균활성 정도를 구명하기 위하여 건조시료를 물(deionized water; nano pure grade), 80% 에탄올(ethanol, Jin chemical parmaceut., Korea), 100% 메탄올(methanol, Merck, Germany)을 용매로 하여 15, 30 및 45분 동안 초음파 추출하고, 그 결과를 하기의 표 5에 나타내었다. DMSO를 용매로 50mg·mL-1 농도로 농축하여 -70℃에서 저장하던 추출물을 agar diffusion 방법을 이용하여 2mg/disc 농도에서 추출조건에 따른 항균활성을 측정하였다.The antimicrobial activity of the extracts was determined by using 100% methanol as a solvent and using Staphylococcus aureaus as a skin extract and skin harmful bacteria. (Deionized water, nano pure grade), 80% ethanol (ethanol, Jin chemical parmaceut., Korea) and 100% methanol (methanol, Merck, Germany) were used for the extraction solvent and extraction time. ) As a solvent for 15, 30 and 45 minutes, and the results are shown in Table 5 below. The antimicrobial activity of the extracts stored at -70 ° C was measured at 2mg / disc concentration using agar diffusion method using DMSO as a solvent at a concentration of 50mg · mL-1.
[표 5][Table 5]
상기 표 5로부터 알 수 있듯이, 담팔수의 S. aureus 억제활성은 부위에 따라 항균력이 크게 달랐으며, 담팔수의 잎은 메탄올을 용매로 30분 동안 초음파 추출(23.3mm) 했을 때 S. aureus 억제활성이 가장 높은 것으로 나타났다. 메탄올(18.6∼23.3mm)과 80% 에탄올 잎 추출물(18.9∼21.8mm)은 S. aureus 억제활성에 큰 차이가 없었으며, 추출시간에 따른 차이도 크지 않은 것으로 나타났다.As can be seen from Table 5, the antimicrobial activity of S. aureus was significantly different depending on the site, and when the methanol extract was applied (23.3 mm) for 30 minutes, Respectively. Methanol (18.6 ~ 23.3mm) and 80% ethanol leaf extract (18.9 ~ 21.8mm) showed no significant difference in S. aureus inhibitory activity.
2-2. 비쭈기나무의 추출 조건에 따른 항균 활성2-2. Antibacterial activity according to the extraction condition of the sibling tree
비쭈기나무의 추출 조건에 따른 항균 활성을 상기와 동일한 방법으로 알아보고, 그 결과를 하기의 표 6에 나타내었다. The antibacterial activity according to the extraction conditions of the sibuch tree was examined in the same manner as above, and the results are shown in Table 6 below.
[표 6][Table 6]
상기 표 6으로부터 알 수 있듯이, 비쭈기나무의 S. aureus 억제활성은 부위에 따라 항균력이 크게 달랐으며, 비쭈기나무 잎의 초음파 30분 메탄올 추출물(21.3mm)과 초음파 45분 80% 에탄올 추출물(21.3mm)에서 S. aureus 억제활성이 가장 높은 것으로 확인되었다. As can be seen from the above Table 6, the S. aureus inhibitory activity of the sibuki bean larvae varied greatly depending on the sites. The 30 minutes methanol extract (21.3 mm) of ultrasound and the 80% ethanol extract (21.3 mm ) Showed the highest inhibitory activity against S. aureus .
실시예 3. 용매 분획물에 따른 항균활성 비교Example 3 Comparison of Antimicrobial Activity According to Solvent Fractions
담팔수의 잎 시료를 100% 메탄올을 용매로 초음파 30분 처리하여 조추출물을 제조하였다. 조추출물을 rotary vacuum evaporator(N-1000, EYELA, Japan)로 감압농축과 동결건조(FD8512, IlShin Lab. Co. Ltd., Korea)를 순서대로 실시하여 고형분 시료 1g을 얻었다. 얻어진 가용성 고형분 시료, 증류수, n-hexane을 1:9:10의 비율로 혼합하여 분획한 후 n-hexane층을 농축하여 n-hexane 분획물을 얻었다. n-hexane 분획 후 수층은 다시 chloroform, ethyl acetate, n-butanol 순으로 순차적으로 용매 분획하였으며, 각각의 분획층을 감압농축한 후 동결건조하여 가용성 분획물을 얻었다. 각 분획물은 증류수에 녹여 항균실험에 사용하였다. 상기 용매 분획물에 따른 담팔수의 staphylococcus aureaus에 대한 억제활성을 확인하고, 그 결과를 하기의 표 7에 나타내었다.The leaf extracts of 100% methanol were used as a solvent for ultrasonic treatment for 30 minutes to prepare crude extracts. The crude extract was concentrated under reduced pressure using a rotary vacuum evaporator (N-1000, EYELA, Japan) and lyophilized (FD8512, Ilshin Laboratories Ltd., Korea) to obtain 1 g of a solid sample. The obtained soluble solid sample, distilled water and n-hexane were mixed and fractionated at a ratio of 1: 9: 10, and the n-hexane fraction was concentrated to obtain n-hexane fraction. After the fractionation of n-hexane, the aqueous layer was further fractionated with chloroform, ethyl acetate and n-butanol in that order. Each fraction was concentrated under reduced pressure and lyophilized to obtain a soluble fraction. Each fraction was dissolved in distilled water and used for antibacterial experiments. The inhibitory activity against the staphylococcus aureaus of the wash- bottom water according to the solvent fraction was confirmed, and the results are shown in Table 7 below.
[표 7][Table 7]
상기 표 7로부터 알 수 있듯이, n-Butanol 분획물에서 23.1mm의 클리어존을 보여 분획 중 가장 높은 활성을 나타내는 것으로 확인되었다. 이는 조추출물(23.3mm)과 유의적으로 비슷하였고, 합성항균제인 methylparaben과 phenoxyethanol와 비교했을 때도 높은 것으로 나타났다. Chloroform 분획물(13.5mm)에서도 phenoxyethanol(11.9mm) 보다 유의적으로 높은 억제활성을 나타내었다. As can be seen from the above Table 7, it was confirmed that the n-butanol fraction exhibits the highest activity among the fractions with a clear zone of 23.1 mm. It was significantly higher than that of crude extract (23.3mm) and higher than that of synthetic antibiotics such as methylparaben and phenoxyethanol. Chloroform fraction (13.5mm) showed significantly higher inhibitory activity than phenoxyethanol (11.9mm).
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적 기술은 단지 바람직한 실시태양일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. something to do. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (15)
상기 상록성 목본식물 추출물은 담팔수[Elaeocarpus sylvestris var. ellipticus (Thunb.) H. Hara]의 잎 추출물, 비쭈기나무(Cleyera japonica Thunb.)의 잎 추출물, 또는 이들의 조합을 메탄올을 용매로 초음파 추출한 것이고,
상기 상록성 목본식물 추출물은 스타피로코쿠스 아우레우스(Staphylococcus aureus), 스타피로코쿠스 에피더미디스 (Staphylococcus epidermidis), 및 프로피오니박테리움 아크네스(Propionibacterium acnes)의 활성을 억제시키는 것을 특징으로 하는 것인, 약제학적 조성물.
A pharmaceutical composition for the prevention or treatment of inflammatory skin diseases,
The above-mentioned herbaceous plant extracts were obtained from Elaeocarpus sylvestris var. a leaf extract of ellipticus (Thunb.) H. Hara], a leaf extract of Cleyera japonica Thunb., or a combination thereof is ultrasonically extracted with methanol as a solvent,
The herbicidal herb extract of the present invention is characterized by inhibiting the activity of Staphylococcus aureus , Staphylococcus epidermidis , and Propionibacterium acnes . ≪ / RTI >
상기 염증성 피부질환은 아토피성 피부염(atopic dermatitis), 접촉성 피부염(contact dermatitis), 지루성 피부염(seborrhea) 및 여드름으로 이루어지는 군으로부터 선택되는 어느 하나인 것을 특징으로 하는 것인, 약제학적 조성물.
The method according to claim 1,
Wherein the inflammatory skin disease is any one selected from the group consisting of atopic dermatitis, contact dermatitis, seborrhea, and acne.
상기 상록성 목본식물 추출물은 상록성 목본식물의 알코올 추출물인 것을 특징으로 하는 것인, 약제학적 조성물.
The method according to claim 1,
Wherein the herbaceous plant extract is an alcoholic extract of an evergreen tree plant.
상기 상록성 목본식물 추출물은 담팔수[Elaeocarpus sylvestris var. ellipticus (Thunb.) H. Hara]의 잎 추출물, 비쭈기나무(Cleyera japonica Thunb.)의 잎 추출물, 또는 이들의 조합을 메탄올을 용매로 초음파 추출한 것이고,
상기 상록성 목본식물 추출물은 스타피로코쿠스 아우레우스(Staphylococcus aureus), 스타피로코쿠스 에피더미디스 (Staphylococcus epidermidis), 및 프로피오니박테리움 아크네스(Propionibacterium acnes)의 활성을 억제시키는 것을 특징으로 하는 것인, 화장료 조성물.
1. A cosmetic composition for improving inflammatory skin diseases, comprising an extract of an herbaceous woody plant,
The above-mentioned herbaceous plant extracts were obtained from Elaeocarpus sylvestris var. a leaf extract of ellipticus (Thunb.) H. Hara], a leaf extract of Cleyera japonica Thunb., or a combination thereof is ultrasonically extracted with methanol as a solvent,
The herbicidal herb extract of the present invention is characterized by inhibiting the activity of Staphylococcus aureus , Staphylococcus epidermidis , and Propionibacterium acnes . ≪ / RTI >
상기 염증성 피부질환은 아토피성 피부염(atopic dermatitis), 접촉성 피부염(contact dermatitis), 지루성 피부염(seborrhea) 및 여드름으로 이루어지는 군으로부터 선택되는 어느 하나인 것을 특징으로 하는 것인, 화장료 조성물.
The method of claim 6, wherein
Wherein the inflammatory skin disease is any one selected from the group consisting of atopic dermatitis, contact dermatitis, seborrhea, and acne.
상기 화장료 조성물은 유연화장수, 수렴화장수, 영양화장수, 영양크림, 마사지크림, 에센스, 아이크림, 아이에센스, 클렌징크림, 클렌징폼, 클렌징워터, 팩, 파우더, 바디로션, 바디크림, 바디오일, 바디에센스, 메이크업 베이스, 파운데이션, 염모제, 샴푸, 린스 및 바디 세정제로 이루어지는 군으로부터 선택되는 것을 특징으로 하는 것인, 화장료 조성물.
The method according to claim 6,
The cosmetic composition of the present invention can be used in cosmetics such as soft longevity, astringent lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, pack, powder, body lotion, body cream, Wherein the cosmetic composition is selected from the group consisting of an essence, a makeup base, a foundation, a hair dye, a shampoo, a rinse and a body cleanser.
상기 상록성 목본식물 추출물은 담팔수[Elaeocarpus sylvestris var. ellipticus (Thunb.) H. Hara]의 잎 추출물, 비쭈기나무(Cleyera japonica Thunb.)의 잎 추출물, 또는 이들의 조합을 메탄올을 용매로 초음파 추출한 것이고,
상기 상록성 목본식물 추출물은 스타피로코쿠스 아우레우스(Staphylococcus aureus), 스타피로코쿠스 에피더미디스 (Staphylococcus epidermidis), 및 프로피오니박테리움 아크네스(Propionibacterium acnes)의 활성을 억제시키는 것을 특징으로 하는 것인, 건강기능식품.
A health functional food for the improvement of inflammatory skin diseases including an herbaceous plant extract,
The above-mentioned herbaceous plant extracts were obtained from Elaeocarpus sylvestris var. a leaf extract of ellipticus (Thunb.) H. Hara], a leaf extract of Cleyera japonica Thunb., or a combination thereof is ultrasonically extracted with methanol as a solvent,
The herbicidal herb extract of the present invention is characterized by inhibiting the activity of Staphylococcus aureus , Staphylococcus epidermidis , and Propionibacterium acnes . Health functional food, which is one.
상기 염증성 피부질환은 아토피성 피부염(atopic dermatitis), 접촉성 피부염(contact dermatitis), 지루성 피부염(seborrhea) 및 여드름으로 이루어지는 군으로부터 선택되는 어느 하나인 것을 특징으로 하는 것인, 건강기능식품.
The method of claim 11, wherein
Wherein said inflammatory skin disease is any one selected from the group consisting of atopic dermatitis, contact dermatitis, seborrhea, and acne.
상기 건강기능식품은 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 껌류, 아이스크림류, 스프, 음료수, 차, 기능수, 드링크제, 알콜 음료 및 비타민 복합제 중 어느 하나의 형태를 갖는 것을 특징으로 하는 것인, 건강기능식품. 12. The method of claim 11,
The health functional food may be any one of meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, gum, ice cream, soup, beverage, tea, functional water, drink, alcoholic beverage, Or a pharmaceutically acceptable salt thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170125363A KR102001069B1 (en) | 2017-09-27 | 2017-09-27 | A composition for improving inflammatory skin disease containing evergreen woody species |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170125363A KR102001069B1 (en) | 2017-09-27 | 2017-09-27 | A composition for improving inflammatory skin disease containing evergreen woody species |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20190036298A KR20190036298A (en) | 2019-04-04 |
KR102001069B1 true KR102001069B1 (en) | 2019-07-17 |
Family
ID=66105582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170125363A KR102001069B1 (en) | 2017-09-27 | 2017-09-27 | A composition for improving inflammatory skin disease containing evergreen woody species |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102001069B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023128630A1 (en) * | 2021-12-28 | 2023-07-06 | 주식회사 제넨셀 | Cosmetic composition for skin improvement comprising extract of elaeocarpus sylvestris var. ellipticus (thunb.) hara |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102381292B1 (en) * | 2019-12-30 | 2022-04-01 | 주식회사 팜스킨 | Composition for ameliorating skin damaged by fine dust containing heavy metal |
WO2022220502A1 (en) * | 2021-04-12 | 2022-10-20 | 주식회사 더퓨쳐 | Anti-bacterial composition containing elaeocarpus sylvestris extract or filtrate thereof as active ingredient |
KR20230024004A (en) * | 2021-08-11 | 2023-02-20 | 주식회사 제넨셀 | Composition for preventing, treating, or improving arthritis comprising Elaeocarpus sylvestris extract or mixture of Elaeocarpus sylvestris extract and sulfasalazine as an active ingredient |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101207560B1 (en) * | 2010-06-28 | 2012-12-03 | 주식회사 코리아나화장품 | Cosmetic composition comprising the extract of Cleyera japonica as active ingredient |
-
2017
- 2017-09-27 KR KR1020170125363A patent/KR102001069B1/en active IP Right Grant
Non-Patent Citations (1)
Title |
---|
Biological and Pharmaceutical Bulletin, 2006, 29(11), pp. 2226-2235* |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023128630A1 (en) * | 2021-12-28 | 2023-07-06 | 주식회사 제넨셀 | Cosmetic composition for skin improvement comprising extract of elaeocarpus sylvestris var. ellipticus (thunb.) hara |
Also Published As
Publication number | Publication date |
---|---|
KR20190036298A (en) | 2019-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102001069B1 (en) | A composition for improving inflammatory skin disease containing evergreen woody species | |
KR100910747B1 (en) | Herb medicine mixture extracts having antifungal, antiacne, skin calming, moisturizing and sebum controlling activities | |
KR102356423B1 (en) | Composition Comprising Complex Strain with Anti-microbial, Skin Moisturizing, Anti-atopy, Skin Barrier, and Anti-wrinkle Property as Active Ingredient | |
KR102348042B1 (en) | Composition for improving skin condition comprising extract of hydrangea serrata | |
KR20100023478A (en) | Composition comprising of plant extract having antimicrobial and antiseptic activity and the use thereof | |
KR102207995B1 (en) | Composition for Anti-microbial, Anti-inflammation, and Skin Hydration Property Comprising Fermented Extract of Momordica charantia as Active Ingredient | |
KR102117218B1 (en) | Composition for improving skin beauty comprising extract of fermented soybean fermented with Aspergillus cristatus strain | |
KR20190080821A (en) | Composition for preventing, improving or treating atopic dermatitis comprising medicinal herb mixed extract as effective component | |
KR102065185B1 (en) | Composition for Improving Skin Conditions with Improved Anti-Bacterial, Anti-inflammatory, Anti-wrinkling, and Skin Whitening Property | |
KR102133101B1 (en) | A Feminine cleanser composition comprising imperata cylindrica leaf and artemisia princeps | |
KR101930264B1 (en) | Cosmetic composition for inhibiting secretion of sebum and for improving acne symptoms containing natural complex extract | |
KR102247810B1 (en) | Composition Comprising Mixed Culture Strain of Lactobacillus sp. SDCM 1003 and SDCM 1105, Culture Fluid, or Culture Fluid Extract thereof as Active Ingredient | |
KR20240004199A (en) | Antibacterial composition containing extract or fractions of Prunus pendula for. ascendens | |
KR102296688B1 (en) | Composition for maintaining vaginal health derived from natural products | |
KR101894807B1 (en) | Antimicrobial composition containing Rosa davurica extract as effective component | |
KR102133268B1 (en) | Prevent, improve and treat acne through the composition of natural extracts | |
KR102228257B1 (en) | Composition for anti-inflammation or anti-acne comprising extract of Immature Citrus Fruit, Curcuma longa and citrus blossom honey | |
KR101769755B1 (en) | A leuconostoc mesenteroides gfc 160704, cosmetic composition including the leuconostoc mesenteroides gfc 160704 or its culture fluid, and manufacturing method of the cosmetic composition | |
JP2017531644A (en) | Hair loss prevention or hair growth promoting composition containing alpine wormwood extract | |
KR102114133B1 (en) | Composition for hair loss prevention or hair growth stimulation comprising scutellaria alpina extract | |
KR102093990B1 (en) | Comppsition comprising mori folium extracts for preventing, treating muscular dystrophy | |
KR101398549B1 (en) | A composition for skin disease improvement comprising extracts or fractions of Eremochloa ophiuroides as an active ingredient | |
KR102154139B1 (en) | Composition comprising fermentation of sap of painted maple, cacao nibs extract and granat extract | |
KR102239415B1 (en) | Composition for improving skin beauty comprising extract of fermented roots of Panax notoginseng by Aspergillus cristatus strain | |
KR20190006285A (en) | Antibacterial composition comprising an extract of schisandra chinesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |